Investment Team

zeshan.jpeg
Zeshan Muhammedi
Managing Partner
Park City, UT

Zeshan is a founder and Managing Partner of MBX Capital. He holds board roles at MBX partner companies Attivare Therapeutics, Cloudcath, Mae Health, AmacaThera, and SecureAire. 

 

Previously, he was the CEO of FundRx, a healthcare and life sciences investment marketplace. Prior to FundRx, he was Managing Partner at Tensile Company, a venture advisory firm. At Tensile, he was an investor and advisor to plant genetics firm Ebbu, Inc (acquired in 2018 for $330mm) and worked with Torreya Partners, a life sciences investment bank, to launch AvaRx, an M&A research platform for the pharma industry. 

 

He is an advisor to BrainMind, a consortium working to support advances in brain science. Zeshan earned his undergraduate degree from Emory University, and is a Kauffman Fellow.

CH7_5511 forbes.jpg
Gurdane Bhutani
Managing Partner
New York, NY

Gurdane is a founder and Managing Partner of MBX Capital. He holds board roles at MBX partner companies Freedom Biosciences, Atlas Health, CareRev, and Contraline. 

Previously, he was the COO of FundRx, a healthcare and life sciences investment marketplace. Prior to FundRx, worked with private equity and corporate clients at Bain & Company and in public finance at Morgan Stanley. He has been an instructor on healthcare finance at the Cleveland Clinic Lerner College of Medicine and guest lecturer in the Wharton School's healthcare management program.  

Gurdane is a Trowell-Harris Scholar at the Yale School of Public Health, and earned his undergraduate degrees, as an A.B Duke Scholar, from Duke University. He was a Lord Rothermere Scholar at the University of Oxford, and is a Kauffman Fellow. 

autri.jpg
Autri Chattopadhyay
Partner & Head of Research
San Diego, CA

Autri is a Partner and Head of Research at MBX Capital. At MBX, Autri works closely with the Managing Partners and the MBX Atom Network to identify and evaluate prospective partner companies.

 

Prior to MBX, Autri worked in commercial innovation at Vertex Pharmaceuticals and was Chief Strategy Officer of Swab56, a nasopharangyeal swab manufacturer. Previously, he was Senior Director of Investments at FundRx, a healthcare and life sciences investment marketplace. Before that, he was a life sciences strategy consultant with Huron Life Sciences/Frankel Group, where he focused on clinical and commercial strategy projects for biopharma clients.

He earned his MBA from Harvard Business School, his MPH from the Dartmouth Institute for Health Policy & Clinical Practice, and his undergraduate degrees from Duke University, where he also conducted neuropharmacology research.